In addition, sputum anti-PAD3/4 antibodies, which were predominately IgA, robustly enhanced the catalytic activity of PAD4, suggesting they could amplify PAD4 activity directly in the lung in a subset of patients with RA. Here, PADI4 is linked to rheumatoid arthritis.